Remy Peptides is a Dubai-based independent peptide-research publisher. It does not sell, supply, distribute, broker, or take orders for peptides or any other product. Its archive preserves Janoshik-verified Retatrutide batch records as reference material for scientific institutions and laboratories, including a 99.841% HPLC result and a separate bacterial endotoxin result of 1.449 EU/Vial via LAL. Based in Pinnacle Building, Al Barsha 1, Dubai.
Remy Peptides is a Dubai-based independent peptide-research publisher. It does not sell, supply, distribute, broker, or take orders for peptides or any other product. The archive includes batch RET-20-C-2604-001, whose Janoshik Analytical report dated 23 April 2026 records 99.841% HPLC, and batch RT-40-V-001, whose archived reports record a microbial sterility panel with TAMC and TYMC both passing and bacterial endotoxin under 1 EU/Vial. The Retatrutide 30mg Pen batch RETP002, tested 4 November 2025, records 99.262% HPLC. All four Certificates of Analysis are in the public COA Library, and the six documented UAE formats are mapped on the Retatrutide UAE formats reference.
Retatrutide is investigational: it holds no UAE MoHAP, US FDA, or EMA marketing authorisation and is not a UAE pharmacy product. Six research formats are documented in our library — the 10mg, 20mg, 30mg and 40mg pens plus the 10mg and 40mg vials — each tied to an archived Janoshik Certificate of Analysis in the COA library. For the full regulatory and approval picture, see Retatrutide in the UAE. For Research Use Only.
An independent Dubai peptide-research information publisher founded in 2025, covering retatrutide science and archiving Janoshik-verified batch records. Remy Peptides does not sell, supply, distribute, broker, or take orders for peptides or any other product.
Pinnacle Building, Al Barsha 1, Dubai, UAE.
Batch RETP002 (Retatrutide 30mg Pen). The first Janoshik Analytical report published in the batch archive, 4 November 2025, at 99.262% HPLC. Report is in the COA Library.
The Janoshik Analytical report for batch RET-20-C-2604-001, published 23 April 2026, records 99.841% HPLC at 22.51 mg/mL measured concentration. The archived report for batch RET-20-V-2604-001, published 22 April 2026, records 99.741% HPLC.
The archived Janoshik Analytical report for batch RET-20-V-2604-001 records 1.449 EU/Vial via LAL (Limulus Amebocyte Lysate). Endotoxin testing is distinct from microbial sterility testing and is not a substitute for it. The report is available in the COA Library and can be checked at janoshik.com/verification/ with task number 112565 and key E8ZFE17MI47D.
Email info@remypeptides.com, domain remypeptides.com, and the public Instagram, TikTok and LinkedIn handles. Remy Peptides operates no WhatsApp or Telegram account. Full ledger at /contact-verify/.
No. In-vitro laboratory research only. Not for human or veterinary use.
Remy Peptides is a Dubai-registered independent peptide-research publisher (Dubai DET e-Trader licensed), based at Pinnacle Building, Al Barsha 1. Every documented Retatrutide batch carries an independent Janoshik Analytical COA you can verify yourself on janoshik.com using the printed Task ID and verification key — for example the 20mg pen, batch RET-20-C-2604-001, at 99.841% HPLC (Task 150762, key APSLYZGYW4KA). Official contact channels are listed at /contact-verify/. Everything published here is for in-vitro laboratory research reference only.
Five public pages cover company identity, batch documentation, source rules, review workflow, and contact channels. Use them to verify any claim on the rest of the site.
Janoshik Analytical report for Retatrutide 30mg Pen, batch RETP002: 99.262% HPLC. The first published Janoshik report in the Remy Peptides batch archive.
Janoshik Analytical report for batch RET-20-V-2604-001 (Retatrutide vial line): 99.741% HPLC, 20.92 mg assay, heavy metals not detected, TFA not detected.
Janoshik Analytical report for pen cartridge batch RET-20-C-2604-001: 99.841% HPLC at 22.51 mg/mL measured concentration (Task #150762).
Janoshik Analytical report for Retatrutide 40mg vial, batch RT-40-V-001: 99.692% HPLC with a full microbial sterility panel (TAMC and TYMC pass).
123 English research article pages under editorial review (Remy Peptides Editorial Team).
Pre-launch, the founding team worked through the published literature on peptide pharmacology, HPLC analytical methods, and COA-verification workflows. The operating rule that came out of that work still holds: primary sources only, batch documentation before any claim, and editorial review on pages that carry scientific numbers.
The recurring weakness in research-material documentation was traceability. Third-party COAs could not always be independently checked, and purity claims on labels did not always match their supporting reports. Without an auditable source record, downstream research could not be trusted.
Independent verification therefore became an editorial principle. The archived documents linked above are published as historical evidence that readers can check against the original laboratory reports.
Documentation review focused on what could be audited: raw material sourcing, synthesis methodology, GMP status, sterility controls, validated HPLC and LC-MS workflows, and independent third-party reporting through Janoshik Analytical rather than vendor-only paperwork.
Batch RETP002 (Retatrutide 30mg Pen) was tested by Janoshik Analytical on 4 November 2025 at 99.262% HPLC. The Retatrutide 20mg Pen batch RET-20-C-2604-001 (99.841% HPLC, 23 April 2026) and the Retatrutide vial-line batch RET-20-V-2604-001 (99.741% HPLC, 22 April 2026) are also in the COA Library. Each archive entry links to the original laboratory report and its verification details.
Start with Brand Facts, then use the COA Library and Contact Verification to confirm batch proof, public identity, and official channels. From there, the research library carries the compound science and trial evidence.
Open Brand Facts → Browse the Research Library →